Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Highlights Advancements of Akston Biosciences' Ambifect® Fc-fusion Platform

Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Overview Company: Akston Biosciences Indication: SARS-CoV-2 Vaccination Drug: AKS-452 Trial Phase: Phase 2 NCT ID: N/A Study Results Akston Biosciences has published the results of their Phase II clinical trial for the AKS-452 vaccine in Nature Vaccines. This study, conducted in the Netherlands, aimed to boost the immune re..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062, Aiming to Target CKD and Proteinuria

BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062 Company: BioCity Biopharma Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: Not provided Overview BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062, Advancing Chronic Kidney Disease Treatment

BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062 Advancing Chronic Kidney Disease Treatment Overview Company: BioCity Biopharma Indication: Chronic kidney disease (CKD), IgA nephropathy (IgAN), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: N/A Background Headquartered in Wuxi, China, BioCity Biopharma is steadfast in its de..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 27.
  • textsms

Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France

Promontory Therapeutics Inc., a clinical stage pharmaceutical company specializing in innovative treatments for cancer, has recently expanded its Phase 2 trial of PT-112 to include patients in France. This exciting development marks the company's first foray into the French market and brings hope to individuals with metastatic castrate-resistant prostate cancer (mCRPC). The trial, which is curre..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 21.
  • textsms

MindBio Therapeutics Begins Pre-Screening Participants for World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder

MindBio Therapeutics Corp. has started the pre-screening process to select participants for its Phase 2 clinical trial on LSD-Microdosing as a treatment for Major Depressive Disorder, making it the first time that take-home approvals have been given for LSD-Microdosing in a clinical trial. &nbsp The initial Phase 2a open-label trial will last for 8 weeks and aims to evaluate the effectiveness of..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Incannex Healthcare Limited has received approval from the Bellberry Human Research Ethics Committee (HREC) for its Phase 2 clinical trial. The trial aims to evaluate the effectiveness of IHL-675A, a unique anti-inflammatory combination drug product, in patients suffering from rheumatoid arthritis (RA). This pivotal trial comes after a successful Phase 1 study where IHL-675A demonstrated excelle..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 14.
  • textsms

Direct Biologics Announces Publication of Significant Survival Benefit with ExoF

Direct Biologics LLC, a biotechnology company in the late stages of development, has recently published groundbreaking findings from their Phase 2 clinical trial in the prestigious Journal CHEST. The trial focused on evaluating the effectiveness of ExoFlo™, a regenerative medicine platform that utilizes extracellular vesicles (EVs) derived from bone marrow-derived mesenchymal stem cells (BM-MSCs..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 13.
  • textsms

Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder &nbsp Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients. PORTICO plans to recruit 188 patients. &nbsp MADRID, Spain and BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms